New Quaternary Ammonium Salts for use in Drug Manufacture

Projektinformationen

QuatSalts

ID Finanzhilfevereinbarung: 690882

DOI

10.3030/690882

Projekt abgeschlossen

EK-Unterschriftsdatum 3 November 2015

Startdatum 1 März 2016

Enddatum 29 Februar 2020

Finanziert unter

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Gesamtkosten

€ 774 000,00

EU-Beitrag

€ 774 000,00

Koordiniert durch

UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II
Italy

Periodic Reporting for period 2 - QuatSalts (New Quaternary Ammonium Salts for use in Drug Manufacture)

Berichtszeitraum: 2018-03-01 bis 2020-02-29

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

The problem being addressed: The ability to develop more environmentally friendly ways of manufacturing pharmaceuticals


Why it's important for society: It is important so that pharmaceuticals can still be made, but with less harmful chemicals being employed in their manufacture which can have a deleterious impact on the environment


What are the overall objectives: To develop, test and implement new catalysts which enable the environmentally friendly manufacture of drugs

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

We have been involved in the design and synthesis of new families of ammonium salts organocatalysts (WP1) and peptide-based catalysts (WP2). We have also started a programme of evaluation of these catalysts.
So far we have successful made a number of these catalysts and they have given some promising results

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The catalysts which we are developing will advance the state of the art insofar as they will avoid the use of precious metals. They will also enable selectivity which is enhanced compared with other catalysts currently available on the market. In terms of the impact, the availability of these catalysts will enable new job creation, securing of existing jobs in Europe (which are under increasing pressure from lower wage economies in the pharmachem sector like India and China. In addition it will lead to new intellectual property which can be patented and might be the basis of formation of new companies.

image for publication